$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417027544 Filed on May 15, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q2
Revenue	$150.0K	$37.00K	$280.0K
YoY Change	-46.43%	-90.24%	-12.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.890M	$2.840M	$2.180M
YoY Change	32.57%	18.33%	50.34%
% of Gross Profit
Research & Development	$1.110M	$1.136M	$850.0K
YoY Change	30.59%	8.4%	11.84%
% of Gross Profit
Depreciation & Amortization	$430.0K	$337.0K	$410.0K
YoY Change	4.88%	29.12%	310.0%
% of Gross Profit
Operating Expenses	$4.010M	$3.973M	$3.030M
YoY Change	32.34%	15.13%	37.1%
Operating Profit		-$3.936M
YoY Change		28.13%
Interest Expense	-$480.0K	$481.0K	-$470.0K
YoY Change	2.13%	48.92%
% of Operating Profit
Other Income/Expense, Net	$10.00K	-$469.0K	$0.00
YoY Change		49.84%	-100.0%
Pretax Income	-$4.330M	-$4.410M	-$3.220M
YoY Change	34.47%	30.09%	70.37%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.330M	-$3.913M	-$2.680M
YoY Change	61.57%	28.89%	41.8%
Net Earnings / Revenue	-2886.67%	-10575.68%	-957.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$486.0K	-$438.8K	-$304.2K
COMMON SHARES
Basic Shares Outstanding	89.12M shares	89.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.090M	$12.42M	$23.01M
YoY Change	-64.84%	-43.26%	142.47%
Cash & Equivalents	$8.088M	$12.42M	$23.01M
Short-Term Investments
Other Short-Term Assets	$280.0K	$370.0K	$260.0K
YoY Change	7.69%	15.63%	1429.41%
Inventory	$30.00K	$60.00K	$20.00K
Prepaid Expenses
Receivables	$175.0K	$130.0K	$484.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.572M	$12.98M	$23.91M
YoY Change	-64.14%	-42.87%	136.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.59M	$25.79M	$25.57M
YoY Change	0.06%	0.07%	196623.08%
Goodwill
YoY Change
Intangibles	$1.823M	$1.895M	$2.092M
YoY Change	-12.86%	-11.41%	-11.36%
Long-Term Investments
YoY Change
Other Assets	$30.00K	$30.00K	$30.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$27.44M	$27.72M	$27.69M
YoY Change	-0.92%	-0.81%	1067.05%
TOTAL ASSETS
Total Short-Term Assets	$8.572M	$12.98M	$23.91M
Total Long-Term Assets	$27.44M	$27.72M	$27.69M
Total Assets	$36.01M	$40.70M	$51.60M
YoY Change	-30.21%	-19.67%	313.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$749.0K	$1.390M	$1.177M
YoY Change	-36.36%	-10.38%	6.61%
Accrued Expenses	$924.0K	$960.0K	$920.0K
YoY Change	0.43%	47.69%	478.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$180.0K	$180.0K	$170.0K
YoY Change	5.88%	5.88%
Total Short-Term Liabilities	$2.013M	$2.621M	$2.291M
YoY Change	-12.13%	7.37%	81.39%
LONG-TERM LIABILITIES
Long-Term Debt	$25.08M	$25.13M	$25.27M
YoY Change	-0.75%	-0.71%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$25.08M	$25.13M	$25.27M
YoY Change	-0.75%	-0.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.013M	$2.621M	$2.291M
Total Long-Term Liabilities	$25.08M	$25.13M	$25.27M
Total Liabilities	$27.10M	$27.75M	$27.56M
YoY Change	-1.67%	0.0%	2081.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.12M	-$67.79M	-$57.59M
YoY Change	25.23%		20.42%
Common Stock	$81.07M	$80.77M	$67.56M
YoY Change	20.0%	27.78%	14.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.914M	$12.95M	$9.937M
YoY Change
Total Liabilities & Shareholders Equity	$36.01M	$40.70M	$51.60M
YoY Change	-30.21%	-19.68%	313.0%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q2
OPERATING ACTIVITIES
Net Income	-$4.330M	-$3.913M	-$2.680M
YoY Change	61.57%	28.89%	41.8%
Depreciation, Depletion And Amortization	$430.0K	$337.0K	$410.0K
YoY Change	4.88%	29.12%	310.0%
Cash From Operating Activities	-$3.760M	-$3.560M	-$2.820M
YoY Change	33.33%	45.9%	133.06%
INVESTING ACTIVITIES
Capital Expenditures	-$520.0K	-$300.0K	-$60.00K
YoY Change	766.67%		-14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$520.0K	-$300.0K	-$60.00K
YoY Change	766.67%		-14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00K	-50.00K	4.000M
YoY Change	-101.0%	-100.28%	48.15%
NET CHANGE
Cash From Operating Activities	-3.760M	-3.560M	-2.820M
Cash From Investing Activities	-520.0K	-300.0K	-60.00K
Cash From Financing Activities	-40.00K	-50.00K	4.000M
Net Change In Cash	-4.320M	-3.910M	1.120M
YoY Change	-485.71%	-125.79%	-21.13%
FREE CASH FLOW
Cash From Operating Activities	-$3.760M	-$3.560M	-$2.820M
Capital Expenditures	-$520.0K	-$300.0K	-$60.00K
Free Cash Flow	-$3.240M	-$3.260M	-$2.760M
YoY Change	17.39%	33.61%	142.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40698000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67468000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57591000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67794000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	9937000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	12946000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51600000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	37000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	80680000	USD
CY2017Q1	us-gaap	Deferred Revenue DeferredRevenue	93000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	24000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	60000	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	USD
CY2017Q1	us-gaap	Security Deposit SecurityDeposit	25000	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	28000	USD
CY2017Q1	us-gaap	Minority Interest MinorityInterest	2000	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	14107000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12948000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24044000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	180000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	170000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2621000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2291000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	25129000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	25265000	USD
CY2017Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2016Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	122000	USD
CY2017Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	4000	USD
CY2016Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	5000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-469000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-313000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	379000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1048000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1136000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	3973000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	481000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2837000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2403000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	3451000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3936000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3072000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4405000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3383000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89109000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81158000	shares
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-492000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-349000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	323000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-4405000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-3385000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3036000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-3913000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	297000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2303000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	673000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5509000	USD
	us-gaap	Operating Expenses OperatingExpenses	7812000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7139000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	17000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1394000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-297000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11809000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7442000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78587000	shares
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1606000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-349000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000	USD
	us-gaap	Interest Expense InterestExpense	1447000	USD
	us-gaap	Interest Expense InterestExpense	323000	USD
	us-gaap	Profit Loss ProfitLoss	-11809000	USD
	us-gaap	Profit Loss ProfitLoss	-7436000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7087000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10203000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	713000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	713000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	940000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	264000	USD
	us-gaap	Depreciation Depreciation	987000	USD
	us-gaap	Depreciation Depreciation	263000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-357000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	110000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	136000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	342000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	37000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	489000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9398000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5250000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	259000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	809000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1068000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1009000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-126000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17662000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-5000	USD
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89109410	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89109410	shares
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	723000	USD
CY2017Q1	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	191000	USD
CY2016Q1	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	303000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	553000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	395000	USD
CY2016Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	323000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1447000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	323000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10592000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12399000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9494000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21893000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-122000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	69000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	76000	USD
	us-gaap	Interest Paid InterestPaid	1449000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	3000	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-28000	USD
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	38000	USD
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	58000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	126000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	525000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-33000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	197000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	87000	USD
	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	71000	USD
	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	0	USD
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	468000	USD
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	17000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6500000	shares
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	337000	USD
CY2017Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	12000	USD
CY2017Q1	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2016Q1	us-gaap	Depreciation Depreciation	261000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92000	USD
CY2016Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	10000	USD
CY2016Q1	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	53000	USD
	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25775000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2139000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	26000	USD
	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2016Q1	us-gaap	Assets Assets	50665000	USD
	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2017Q1	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	200000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	207000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	713000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	196000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	191000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12273334	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	150000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.30
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.30
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.30
	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	323000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	993000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	196000	USD
CY2015Q2	ibio	Registration Common Stock RegistrationCommonStock	15000000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	2100000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	2100000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2100000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2100000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2100000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.40
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1566000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	605000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5365000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3537000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3273000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3939000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3036000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10229000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7087000	USD
CY2016Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4043000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	IBIO
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89118510	shares
CY2017Q1	us-gaap	Liabilities Liabilities	27750000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	27556000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	199000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	58800000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	69300000	USD
CY2017Q1	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	481000	USD
	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	1447000	USD
	ibio	Sub Lease Expiration Period SubLeaseExpirationPeriod	P34Y
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2100000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1895000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2092000	USD
CY2017Q1	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	1500000	USD
CY2016Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	571000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	66000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	34000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	200000	USD
CY2017Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	784000	USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	623000	USD
CY2017Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.001
CY2016Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.001
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89118510	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89118510	shares
CY2017Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	225000	USD
CY2016Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	244000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	670000	USD
CY2017Q1	us-gaap	Revenue From Grants RevenueFromGrants	44000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	7000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	84000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	7000	USD
CY2017Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	481000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2178000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	15000000	USD
	us-gaap	Stock Issued1 StockIssued1	12499000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	26000000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio was established as a public company in August 2008 as the result of a spin-off from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBioDefense Biologics LLC (“iBioDefense”) iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Peptide Therapeutics LLC (“iBio Peptide”) iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Manufacturing LLC (“iBio Manufacturing”) iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO LLC (“iBio CMO”) iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99.99</font>% of iBio CMO. See Note 9 for a further discussion.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sub-landlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font> square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	116665	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.54
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5432000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0237	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0438	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27360000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26179000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y
CY2016Q1	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	323000	USD
	ibio	Capital Lease Obligation Description CapitalLeaseObligationDescription	The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to approximately $29,000 and $75,000 for the three and nine months ended March 31, 2017, respectively. The percentage rent for the fiscal year ending June 30, 2016 amounted to approximately $27,000.
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	9100	shares
CY2017Q1	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	26000	USD
CY2016Q1	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0	USD
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	26000	USD
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0	USD
CY2016Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	16000	USD

Files In Submission

Name	View Source	Status
0001144204-17-027544-index-headers.html	Edgar Link	pending
0001144204-17-027544-index.html	Edgar Link	pending
0001144204-17-027544.txt	Edgar Link	pending
0001144204-17-027544-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20170331.xml	Edgar Link	completed
ibio-20170331.xsd	Edgar Link	pending
ibio-20170331_cal.xml	Edgar Link	unprocessable
ibio-20170331_def.xml	Edgar Link	unprocessable
ibio-20170331_lab.xml	Edgar Link	unprocessable
ibio-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466525_10q.htm	Edgar Link	pending
v466525_ex31-1.htm	Edgar Link	pending
v466525_ex31-2.htm	Edgar Link	pending
v466525_ex32-1.htm	Edgar Link	pending
v466525_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2017 Q2 Form 10-Q Financial Statement

#000114420417027544 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2017 Q2 Form 10-Q Financial Statement

#000114420417027544 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio